首頁 > 市場調查報告書 > 製藥

呼吸器

肺藥市場：按藥物類別、應用、分銷渠道、地區 - 規模、份額、前景、機會分析，2022-2030

市場調查報告書

商品編碼

1110119

肺藥市場：按藥物類別、應用、分銷渠道、地區 - 規模、份額、前景、機會分析，2022-2030

Pulmonary Drugs Market, by Drug Class, by Application, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年07月14日 | 出版商:

Coherent Market Insights | 英文 304 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

肺藥用於治療影響肺部的疾病。肺部藥物用於治療普通感冒等輕度疾病到哮喘等長期疾病。這些藥物有多種形式，包括口服片劑、口服液、注射劑和吸入器。吸入器將藥物直接輸送到肺部，在那裡它直接作用於肺組織，從而最大限度地減少全身副作用。

市場動態

推動肺藥市場增長的主要因素包括慢性呼吸道疾病發病率的增加、吸煙、政府和非政府舉措。根據疾病控制和預防中心 (CDC) 的數據，2015 年美國有 2500 萬人患有哮喘病，這相當於每 13 個美國人中就有 1 個患有哮喘病。 620 萬 18 歲以下的人患有哮喘。哮喘每年造成 1420 萬次就診和 180 萬次救護車就診。此外，大量品牌藥物的專利到期、研發資金以及創新產品的推出預計將成為預測期內市場增長的主要因素。例如，在 2017 年，葛蘭素史克獲得了美國 FDA 對一種名為 Trelegy Ellipta 的專有三合一吸入器的批准，用於治療慢性肺病。 Trelegy Ellipta 將三種治療方法結合到一個吸入器中，從而為患者提供新的治療選擇。然而，大量未確診的患者以及與服用這些導致腎臟問題導致不良事件的藥物相關的副作用預計將限制市場的增長。

本研究的主要特點

本報告對肺藥市場進行了深入分析，提供了以 2017 年為基準年的預測期（2017-2025 年）的市場規模和累計年增長率 (CAGR %)。
說明不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
該研究還提供了有關市場驅動因素、限制因素、機遇、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
根據以下參數來描述全球肺部藥物市場的主要參與者 - 公司概況、財務業績、產品組合、市場存在、分銷戰略、關鍵發展、戰略和未來計劃
本研究涵蓋的主要公司包括 Sanofi SA、Meda Pharmaceuticals、Circassia Pharmaceuticals Plc.、AstraZeneca Plc.、GlaxoSmithKline Plc.、Mallinckrodt Pharmaceuticals Plc.、Cheisi Farmaceuticals S.p.A、Zambon Company S.p.A、Alaxia SAS 和 Merck Sharp & Dohme 有限公司
本報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、技術升級、市場擴張和營銷策略做出明智的決策。
全球肺治療市場報告迎合了該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。
將通過用於分析肺治療市場的各種戰略矩陣，為利益相關方制定決策提供便利。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第2章市場展望

舉報內容
- 市場定義和範圍
執行摘要
- 市場快照：按藥物類別
- 市場快照：按應用
- 市場快照：按分銷渠道
- 市場概況：按地區劃分
連貫的機會圖 (COM)

第 3 章市場動態、監管和趨勢分析

市場動態
- 驅動程序
- 限制因素
- 市場機會
監管場景
管道分析
促銷活動和活動
供應鏈分析
PEST 分析
流行病學

第 4 章全球肺藥市場 - 冠狀病毒 (COVID-19) 大流行的影響

整體影響
政府舉措
COVID-19 對市場的影響

第 5 章。2017-2030 年按藥物類別分列的全球肺藥市場

吸入性皮質類固醇
長效β2激動劑
抗組胺藥
血管擴張劑
短效 β-2 激動劑
其他

第 6 章。2017-2030 年按應用分列的全球肺藥市場

支氣管哮喘和慢性阻塞性肺病
過敏性鼻炎
肺動脈高壓
囊性纖維化
其他

第 7 章。2017-2030 年全球肺藥市場，按分銷渠道分列

醫院藥房
零售藥房
電子商務

第 8 章。全球肺藥市場：按地區劃分，2017-2030 年

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
英國
德國
意大利
法國
西班牙
俄羅斯
其他歐洲
亞太地區
中國
印度
日本
東盟
澳大利亞
韓國
其他亞太地區
中東
海合會
以色列
其他中東地區
非洲
北非
中非
南非

第 9 章競爭格局

熱圖分析
市場份額分析（3x3 矩陣）
公司簡介
- Sanofi SA
- Meda Pharmaceuticals
- Circassia Pharmaceuticals Plc.
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Mallinckrodt Pharmaceuticals Plc.
- Cheisi Farmaceutici S.p.A
- Zambon Company S.p.A
- Alaxia SAS
- Merck Sharp & Dohme Limited

第10章章節

參考文獻
調查手法介紹

簡介目錄

Product Code: CMI1285

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

Market Dynamics

The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.

Key features of the study:

This report provides in-depth analysis of pulmonary drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 - 2025), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global pulmonary drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market

Detailed Segmentation:

Global Pulmonary Drugs Market, By Drug Class:
- Inhaled Corticosteroids
- Long Acting Beta-2 Agonists
- Antihistamines
- Vasodilators
- Short Acting Beta-2 Agonists
- Others
Global Pulmonary Drugs Market, By Application:
- Asthma & COPD
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
- Others
Global Pulmonary Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
Global Pulmonary Drugs Market, By Geography:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Sanofi SA*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments
- Meda Pharmaceuticals
- Circassia Pharmaceuticals Plc.
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Mallinckrodt Pharmaceuticals Plc.
- Cheisi Farmaceutici S.p.A
- Zambon Company S.p.A
- Alaxia SAS
- Merck Sharp & Dohme Limited

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
Pipeline Analysis
Promotional Activities and Campaigns
Supply Chain Analysis
PEST Analysis
Epidemiology

4. Global Pulmonary Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Pulmonary Drugs Market, By Drug Class, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Inhaled Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Long Acting Beta-2 Agonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Antihistamines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Vasodilators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Short Acting Beta-2 Agonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

6. Global Pulmonary Drugs Market, By Application , 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Asthma & COPD
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Allergic Rhinitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Pulmonary Arterial Hypertension
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Cystic Fibrosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

7. Global Pulmonary Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
E-Commerce
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

8. Global Pulmonary Drugs Market, By Region, 2017 - 2030, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
UK
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
North Africa
Central Africa
South Africa